skip to content

Cambridge Academy of Therapeutic Sciences


The CATS-Milner Therapeutic Perspectives Series has recently been launched. The aim of this regular series is to bring together experts from a number of separate but closely linked sectors, to discuss the potentials and challenges within translational research and how we as an ecosystem can work together to create the right environment to support new treatments for patients. The series is aimed at a mixed academic-industry audience and draws on expert speakers from across academia, industry, medicine, investors, policy and funding.

The series is a joint venture between the Cambridge Academy of Therapeutic Sciences and the Milner Therapeutics Institute, two teams at the University who work across the traditional boundaries between disciplines and between academia and industry to facilitate and transform pioneering research into new therapies as well as support the education and training of the next generation of world-leading researchers. If you would like to connect, please look at the websites or get in touch via email.

The series is currently paused and will resume in October 2021. Details of previous events in the series can be found below; please note that these events take place live and are not recorded.

If you have questions about this series or would like to join our email list for event updates, please email




Previous Events:


How can we make clinically meaningful progress in microbiome-related therapeutics development?

1st July 2021

Chair: Dr Mat Robinson – VP Translational Biology, Microbiotica


Dr Kiran Patil – MRC Toxicology Unit Programme Lead, University of Cambridge

Professor Denise Kelly – Investment Advisor, Seventure Partners

Professor Julian Marchesi – Professor of Digestive Health, Imperial College London

Dr Kristin Wannerberger – Director R&D Alliance Management, Ferring Pharmaceuticals

Professor Fergus Shanahan – Professor and Chair of the Department of Medicine, University College Cork



Translating breakthroughs in Alzheimer’s Disease into new treatments

10th June 2021

Chair: John Skidmore, Chief Scientific Officer, ALBORADA Drug Discovery Institute, funded by Alzheimer’s Research UK


David Rubinsztein, Cambridge Institute for Medical Research, University of Cambridge

James Rowe, MRC Cognition and Brain Sciences Unit, Department of Clinical Neurosciences, University of Cambridge

Susan Kohlhaas, Director of Research, Alzheimer’s Research UK

Peter Larsen, J&J Innovation